StockMacro
Company, fund or insider

Help

Menu

Avalo Therapeutics

$6.76 -58% in 6 monthsMarket cap $390.9M

AVTX on XNAS, Health Care, Avalo Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 45% in one month, though cash of $462.8M exceeds the $390.3M market value.

  • BadNet loss of $88.7M over the last 12 months
  • GoodInstitutional holders rose 16% to 146 in one quarter

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Industry
Pharmaceutical preparations (Health Care)
Employees
33
Website
avalotx.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $18.9M.
Quarter to 31 Dec 2021: revenue $219K, net income -$19.2MQuarter to 31 Dec 2021: revenue $219K, net income -$19.2MQuarter to 31 Mar 2022: revenue $1.2M, net income -$22.1MQuarter to 31 Mar 2022: revenue $1.2M, net income -$22.1MQuarter to 30 Jun 2022: revenue $1.0M, net income -$13.0MQuarter to 30 Jun 2022: revenue $1.0M, net income -$13.0MQuarter to 30 Sep 2022: revenue $14.9M, net income $3.2MQuarter to 30 Sep 2022: revenue $14.9M, net income $3.2MQuarter to 31 Dec 2022: revenue $896K, net income -$9.8MQuarter to 31 Dec 2022: revenue $896K, net income -$9.8MQuarter to 31 Mar 2023: revenue $475K, net income -$10.0MQuarter to 31 Mar 2023: revenue $475K, net income -$10.0MQuarter to 30 Jun 2023: revenue $643K, net income -$8.2MQuarter to 30 Jun 2023: revenue $643K, net income -$8.2MQuarter to 30 Sep 2023: revenue $236K, net income -$5.2MQuarter to 30 Sep 2023: revenue $236K, net income -$5.2MQuarter to 31 Dec 2023: revenue $571K, net income -$8.2MQuarter to 31 Dec 2023: revenue $571K, net income -$8.2MQuarter to 31 Mar 2024: revenue $0, net income -$121.3MQuarter to 31 Mar 2024: revenue $0, net income -$121.3MQuarter to 30 Jun 2024: revenue $0, net income $98.5MQuarter to 30 Jun 2024: revenue $0, net income $98.5MQuarter to 30 Sep 2024: revenue $249K, net income $23.0MQuarter to 30 Sep 2024: revenue $249K, net income $23.0MQuarter to 31 Dec 2024: revenue $192K, net income -$35.3MQuarter to 31 Dec 2024: revenue $192K, net income -$35.3MQuarter to 31 Mar 2025: revenue –, net income -$13.1MQuarter to 30 Jun 2025: revenue –, net income -$20.8MQuarter to 30 Sep 2025: revenue $0, net income -$30.6MQuarter to 30 Sep 2025: revenue $0, net income -$30.6MQuarter to 31 Dec 2025: revenue $59K, net income -$13.7MQuarter to 31 Dec 2025: revenue $59K, net income -$13.7MQuarter to 31 Mar 2026: revenue –, net income -$19.6MQuarter to 30 Jun 2026: revenue –, net income -$36.4MQuarter to 30 Sep 2026: revenue –, net income -$18.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $121.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$18.9M
30 Jun 2026–-$36.4M
31 Mar 2026–-$19.6M
31 Dec 2025$59K-$13.7M
30 Sep 2025$0-$30.6M
30 Jun 2025–-$20.8M
31 Mar 2025–-$13.1M
31 Dec 2024$192K-$35.3M
30 Sep 2024$249K$23.0M
30 Jun 2024$0$98.5M
31 Mar 2024$0-$121.3M
31 Dec 2023$571K-$8.2M
30 Sep 2023$236K-$5.2M
30 Jun 2023$643K-$8.2M
31 Mar 2023$475K-$10.0M
31 Dec 2022$896K-$9.8M
30 Sep 2022$14.9M$3.2M
30 Jun 2022$1.0M-$13.0M
31 Mar 2022$1.2M-$22.1M
31 Dec 2021$219K-$19.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$88.7M -$99.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -33.6% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $462.8M $111.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$462.8M (net cash) -$111.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $7.55
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.90 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Avalo TherapeuticsAVTX (this company) $390.9Mloss–––
Opus GeneticsIRD $385.7Mloss48.7-46%–
RezoluteRZLT $379.2Mloss–––
Phathom PharmaceuticalsPHAT $378.8Mloss1.4+87%-30.2%
Ovid TherapeuticsOVID $415.2Mloss286-78%–
CorMedixCRMD $419.2M6.61.0–15.5%

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$395K

bought $0, sold $395K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+16%

146 13F filers vs 126

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

71.6M shares held by 13F filers (30 Sep 2026) of 57.8M outstanding (2 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

15%

8.9M shares sold short (30 Oct 2026) of 57.8M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.1

8.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-26%

12.0M shares sold short in the report before, 8.9M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

37%

37% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 46%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

17

17 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

17×

17 articles in the last 7 days; its usual week has 1.

Price $6.76 on 20 Nov 2026, -62% over 12 months (12-month range $6.63 to $22.87)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $8.3M in the last 12 months (the 12 months before: -$163K).
Revenue per quarter. Revenue $59K in the latest quarter, -69% on a year earlier.
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 146 13F filers reported holding it in the latest 13F quarter, +125% on a year earlier.
Lobbying spend. Lobbying spend: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
5 Nov 20268-K and other filingsA major agreement ended
23 Jun 20268-K and other filingsDirector or officer change
12 Jun 20268-K and other filingsDirector or officer change
8 Jun 20268-K and other filingsDirector or officer change
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 30 vs usual 7.50 (2026-03-31); 6.0x the same period a year earlier
14 Apr 2026Sharp changeShort interest spike: short interest spike, 5.5M vs usual 723K (2026-03-31); 47.9x the same period a year earlier
31 Mar 2026Sharp changeShort interest spike: short interest spike, 4.1M vs usual 183K (2026-03-13); 42.5x the same period a year earlier
27 Mar 20268-K and other filingsDirector or officer change
27 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Mar 2026Sharp changeShort interest spike: short interest spike, 3.7M vs usual 141K (2026-02-27); 40.6x the same period a year earlier
3 Mar 2026Sharp changeShort interest spike: short interest spike, 3.6M vs usual 117K (2026-02-13); 47.3x the same period a year earlier
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 30 vs usual 6.50 (2025-12-31); 4.3x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 3.2M vs usual 108K (2026-01-30); 73.6x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 3.0M vs usual 98K (2026-01-15); 53.4x the same period a year earlier
13 Jan 2026Sharp changeShort interest spike: short interest spike, 2.6M vs usual 93K (2025-12-31); 127.5x the same period a year earlier
30 Dec 2025Sharp changeShort interest spike: short interest spike, 1.9M vs usual 90K (2025-12-15); 81.1x the same period a year earlier
16 Dec 2025Sharp changeShort interest spike: short interest spike, 1.8M vs usual 88K (2025-11-28); 354.2x the same period a year earlier
2 Dec 2025Sharp changeShort interest spike: short interest spike, 1.8M vs usual 85K (2025-11-14); 188.3x the same period a year earlier
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 31 vs usual 6.50 (2025-09-30); 2.8x the same period a year earlier
18 Nov 2025Sharp changeShort interest spike: short interest spike, 1.3M vs usual 80K (2025-10-31); 133.7x the same period a year earlier
28 Oct 2025Sharp changeShort interest spike: short interest spike, 1.3M vs usual 66K (2025-10-15); 26.4x the same period a year earlier
14 Oct 2025Sharp changeShort interest spike: short interest spike, 1.2M vs usual 56K (2025-09-30); 22.9x the same period a year earlier
1 Oct 20258-K and other filingsDirector or officer change
22 Sep 20258-K and other filingsDirector or officer change
22 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Jun 20258-K and other filingsDirector or officer change
5 Jun 20258-K and other filingsA major agreement ended
26 Mar 20258-K and other filingsDirector or officer change
2 Jan 20258-K and other filingsDirector or officer change
2 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Aug 20248-K and other filingsDirector or officer change
16 Jul 20248-K and other filingsDirector or officer change
24 Jun 20248-K and other filingsDirector or officer change
23 May 20248-K and other filingsDelisting notice or listing transfer
9 Apr 20248-K and other filingsPrivate placement of securities (Form D)
28 Mar 20248-K and other filingsDirector or officer change
28 Mar 20248-K and other filingsDelisting notice or listing transfer
28 Mar 20248-K and other filingsCompleted an acquisition or asset sale
28 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Jan 2024Lobbying filinglobbying engagement terminated (BURRELL INTERNATIONAL GROUP LLC)
2 Jan 2024Sharp changeShort interest spike: short interest spike, 12.6M vs usual 46K (2023-12-15); 309.9x the same period a year earlier
12 Dec 2023Sharp changeShort interest spike: short interest spike, 10.2M vs usual 43K (2023-11-30); 273.5x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 18.1M vs usual 42K (2023-11-15); 529.8x the same period a year earlier
16 Nov 20238-K and other filingsDelisting notice or listing transfer
14 Nov 2023Sharp changeShort interest spike: short interest spike, 12.9M vs usual 41K (2023-10-31); 364.8x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 12.4M vs usual 41K (2023-10-13); 255.8x the same period a year earlier
31 Oct 20238-K and other filingsCompleted an acquisition or asset sale
17 Oct 2023Sharp changeShort interest spike: short interest spike, 17.5M vs usual 41K (2023-09-29); 400.1x the same period a year earlier
3 Oct 2023Sharp changeShort interest spike: short interest spike, 3.1M vs usual 41K (2023-09-15); 46.2x the same period a year earlier
19 Sep 2023Sharp changeShort interest spike: short interest spike, 959K vs usual 41K (2023-08-31); 18.2x the same period a year earlier
13 Sep 20238-K and other filingsDelisting notice or listing transfer
29 Aug 2023Sharp changeShort interest spike: short interest spike, 957K vs usual 41K (2023-08-15); 11.0x the same period a year earlier
15 Aug 2023Sharp changeShort interest spike: short interest spike, 1.1M vs usual 41K (2023-07-31); 10.9x the same period a year earlier
8 Aug 20238-K and other filingsDelisting notice or listing transfer
1 Aug 2023Sharp changeShort interest spike: short interest spike, 887K vs usual 41K (2023-07-14); 9.3x the same period a year earlier
18 Jul 2023Sharp changeShort interest spike: short interest spike, 628K vs usual 41K (2023-06-30); 0.7x the same period a year earlier
14 Jun 2023Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 8 filing(s) in 30 days, value_usd total 209K)
21 Apr 20238-K and other filingsA major agreement ended
14 Nov 20228-K and other filingsCompleted an acquisition or asset sale
8 Nov 2022Sharp changeQuarterly revenue change: quarterly revenue change, 14.9M vs usual 1.1M (2022-09-30); 11.1x the same period a year earlier
11 Aug 20228-K and other filingsDirector or officer change
11 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Mar 20228-K and other filingsDelisting notice or listing transfer
18 Feb 20228-K and other filingsDirector or officer change
8 Feb 20228-K and other filingsDirector or officer change
12 Jan 2022Sharp changeClustered insider buying: clustered insider buying (6 independent filers, 6 filing(s) in 30 days, value_usd total 668K)
6 Dec 20218-K and other filingsDirector or officer change
Insider net buying (open market)
Month from 1 Dec 2021: $23K published
Month from 1 Jan 2022: $1.4M published
Month from 1 Feb 2022: $232K published
Month from 1 Mar 2022: $608K published
Month from 1 Dec 2022: $9K published
Month from 1 Feb 2023: $0 published
Month from 1 Apr 2023: $292K published
Month from 1 May 2023: $204K published
Month from 1 Jun 2023: -$968K published
Month from 1 Nov 2024: $13K published
Month from 1 Nov 2025: -$163K published
Month from 1 Mar 2026: -$412K published
Month from 1 Apr 2026: -$353K published
Month from 1 May 2026: -$5.5M published
Month from 1 Jun 2026: -$37K published
Month from 1 Jul 2026: -$113K published
Month from 1 Aug 2026: -$1.5M published
Month from 1 Sep 2026: -$395K published
Revenue per quarter
Quarter ended 31 Dec 2021: $219K, -85% on a year earlier; public on 3 Mar 2022
Quarter ended 31 Mar 2022: $1.2M, +148% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $1.0M, -69% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $14.9M, +1007% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $896K, +309% on a year earlier; public on 30 Mar 2023
Quarter ended 31 Mar 2023: $475K, -60% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $643K, -38% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $236K, -98% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $571K, -36% on a year earlier; public on 30 Mar 2024
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $249K, +5.5% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $192K, -66% on a year earlier; public on 21 Mar 2025
Quarter ended 30 Sep 2025: $0, -100% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $59K, -69% on a year earlier; public on 24 Mar 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $0, -100% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $56K; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $39K; public on 8 Nov 2022
Quarter ended 31 Mar 2023: $158K; public on 5 May 2023
Quarter ended 30 Jun 2023: $0, -100% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $0; public on 30 Mar 2024
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $0; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $0; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $0; public on 21 Mar 2025
Institutional holders (13F filers)
31 Dec 2021 report: 71; public on 14 Feb 2022
31 Mar 2022 report: 68; public on 16 May 2022
30 Jun 2022 report: 53; public on 15 Aug 2022
30 Sep 2022 report: 25; public on 14 Nov 2022
31 Dec 2022 report: 28; public on 14 Feb 2023
31 Mar 2023 report: 32; public on 15 May 2023
30 Jun 2023 report: 25; public on 14 Aug 2023
30 Sep 2023 report: 25; public on 14 Nov 2023
31 Dec 2023 report: 12; public on 14 Feb 2024
31 Mar 2024 report: 18; public on 15 May 2024
30 Jun 2024 report: 20; public on 14 Aug 2024
30 Sep 2024 report: 29; public on 14 Nov 2024
31 Dec 2024 report: 33; public on 14 Feb 2025
31 Mar 2025 report: 34; public on 15 May 2025
30 Jun 2025 report: 35; public on 14 Aug 2025
30 Sep 2025 report: 65; public on 14 Nov 2025
31 Dec 2025 report: 82; public on 17 Feb 2026
31 Mar 2026 report: 95; public on 15 May 2026
30 Jun 2026 report: 126; public on 14 Aug 2026
30 Sep 2026 report: 146; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $30K published
Quarter from 1 Apr 2022: $30K published
Quarter from 1 Jul 2022: $30K published
Quarter from 1 Oct 2022: $30K published
Quarter from 1 Jan 2023: $30K published
Quarter from 1 Apr 2023: $30K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 146 (30 Sep 2026), 4.4× its normal reading; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $8.3M in the last 12 months (the 12 months before: -$163K).
  • Revenue per quarter: Revenue $59K in the latest quarter, -69% on a year earlier.
  • Capital spending per quarter: Capital spending $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 3 sales, $395K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Sep 2026Christopher Ryan SullivanChief Financial OfficerSellplanned in advance (10b5-1); after exercising options12,394$16.33$202KForm 4
11 Sep 2026Christopher Ryan SullivanChief Financial OfficerSellplanned in advance (10b5-1); after exercising options10,185$17.62$179KForm 4
1 Sep 2026Mittie DoyleChief Medical OfficerSellplanned in advance (10b5-1); after exercising options679$20.00$14KForm 4
19 Aug 2026Mittie DoyleChief Medical OfficerSellplanned in advance (10b5-1); after exercising options1,000$20.00$20KForm 4
19 Aug 2026Christopher Ryan SullivanChief Financial OfficerSellplanned in advance (10b5-1); after exercising options72,725$19.94$1.5MForm 4
12 Aug 2026Jennifer RileyChief Strategy OfficerSell2,655$19.59$52KForm 4
12 Aug 2026Mittie DoyleChief Medical OfficerSellplanned in advance (10b5-1); after exercising options679$20.00$14KForm 4
29 Jul 2026Mittie DoyleChief Medical OfficerSellplanned in advance (10b5-1); after exercising options1,000$20.00$20KForm 4

146 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 33 opened a position, 15 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)5.3M9.08%$80.5M+150K+2.9%
BlackRock, Inc.5.0M8.58%$76.0M+594K+14%
Farallon Capital Management, L.L.C.4.0M6.87%$60.9M+1.5M+59%
Deep Track Capital, LP3.6M6.24%$55.3MNo change
Caligan Partners LP3.3M5.65%$50.1M+104K+3.3%
Affinity Asset Advisors, LLC3.2M5.61%$49.7M+345K+12%
TCG Crossover Management, LLC3.0M5.22%$46.3MNo change
State Street Corp2.6M4.43%$39.3M-326K-11%
Avoro Capital Advisors LLC2.4M4.11%$36.5M+44K+1.9%
Vanguard Capital Management LLC2.3M3.90%$34.6M-8,001-0.4%

Federal contracts

All 2 federal contracts

No new award in 12 months; the latest was signed 18 Jul 2016. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
18 Jul 2016Department of Health and Human ServicesNational Institutes of Health$757KEARLY STAGE DEVELOPMENT OF A SELECTIVE KAPPA OPIOID RECEPTOR (KOR) ANTAGONIST TO TREAT ALCOHOL USE DISORDERGrantUSAspending
7 Apr 2016Department of Health and Human ServicesNational Institutes of Health$1.0MCERC-501 KAPPA ANTAGONIST FOR NICOTINE DEPENDENCEGrantUSAspending

In 12 months: 4 director or officer changes, 3 major agreements, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
5 Nov 2026Signed a major agreement; A major agreement ended8-K
23 Jun 2026Director or officer change8-K
12 Jun 2026Director or officer changeSame filing: sold shares privately, changed shareholder rights, changed its bylaws or fiscal year8-K
8 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
6 May 2026Signed a major agreement8-K
28 Apr 2026Signed a major agreement8-K
27 Mar 2026Director or officer change8-K
1 Oct 2025Director or officer change8-K

Reported lobbying spend: $30K in Q1 2023, $30K in Q4 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2023EndedBurrell International Group LLCfor Avalo TherapeuticsNot statedFiling
26 Mar 2021NewBurrell International Group LLCfor Avalo TherapeuticsAppropriations and funding for client projects, products, and services; Drug Pricing, Rare Disease Cures, cell and gene therapy.Budget, Health issues, Pharmacy, MEDFiling

The 5 newest of 98 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

18 Nov 2025confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Avalo Therapeutics (AVTX): saw 31 13F filers open a new position in the quarter ended 30 Sep 2025, 2.8× the same quarter last year, while it had 4.1M shares sold short in the 13 Mar 2026 report, 43× the same report last year. Two unrelated kinds of activity within 168 days.

  • Short interest and volume: Short interest spike, became public on 25 Oct 2025
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2025
  • Short interest and volume: Short interest spike, became public on 13 Nov 2025
  • Short interest and volume: Short interest spike, became public on 26 Nov 2025
  • Short interest and volume: Short interest spike, became public on 10 Dec 2025
  • Short interest and volume: Short interest spike, became public on 25 Dec 2025
  • Short interest and volume: Short interest spike, became public on 13 Jan 2026
  • Short interest and volume: Short interest spike, became public on 28 Jan 2026
  • Institutional holdings: Many funds opening a new position, became public on 17 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Feb 2026
  • Short interest and volume: Short interest spike, became public on 26 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Mar 2026
  • Short interest and volume: Short interest spike, became public on 25 Mar 2026
  • Short interest and volume: Short interest spike, became public on 11 Apr 2026
2023-09-30: 92023-12-31: 32024-03-31: 82024-06-30: 62024-09-30: 112024-12-31: 72025-03-31: 52025-06-30: 42025-09-30: 31
The quarter ended 30 Sep 2025 against the 8 quarters before it. this quarterearliernormal: 6.5
See the evidence (14 changes)

Short interest and volume: Short interest spike became public on 25 Oct 2025

Avalo Therapeutics had 1.3M shares sold short in the 15 Oct 2025 report, 26× the same report last year.

This period
1.3M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
66K
Typical spread (median absolute deviation)
27K
How far from its usual level
+24.7
Same report last year
49K
History used
1,506 days
2024-10-15: 49K2024-10-31: 10K2024-11-15: 9,7752024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M
the 15 Oct 2025 report24 earlier reportsnormal: 66K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Nov 2025

Avalo Therapeutics saw 31 13F filers open a new position in the quarter ended 30 Sep 2025, 2.8× the same quarter last year.

This period
31 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.2
Same quarter last year
11
History used
1,461 days
2023-09-30: 92023-12-31: 32024-03-31: 82024-06-30: 62024-09-30: 112024-12-31: 72025-03-31: 52025-06-30: 42025-09-30: 31
the quarter ended 30 Sep 20258 earlier quartersnormal: 6.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 13 Nov 2025

Avalo Therapeutics had 1.3M shares sold short in the 31 Oct 2025 report, 134× the same report last year.

This period
1.3M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
80K
Typical spread (median absolute deviation)
36K
How far from its usual level
+23.6
Same report last year
10K
History used
1,522 days
2024-10-31: 10K2024-11-15: 9,7752024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M
the 31 Oct 2025 report24 earlier reportsnormal: 80K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Nov 2025

Avalo Therapeutics had 1.8M shares sold short in the 14 Nov 2025 report, 188× the same report last year.

This period
1.8M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
85K
Typical spread (median absolute deviation)
39K
How far from its usual level
+30.4
Same report last year
9,775
History used
1,536 days
2024-11-15: 9,7752024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M
the 14 Nov 2025 report24 earlier reportsnormal: 85K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Dec 2025

Avalo Therapeutics had 1.8M shares sold short in the 28 Nov 2025 report, 354× the same report last year.

This period
1.8M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
88K
Typical spread (median absolute deviation)
42K
How far from its usual level
+28.2
Same report last year
5,218
History used
1,550 days
2024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M
the 28 Nov 2025 report24 earlier reportsnormal: 88K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Dec 2025

Avalo Therapeutics had 1.9M shares sold short in the 15 Dec 2025 report, 81× the same report last year.

This period
1.9M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
90K
Typical spread (median absolute deviation)
44K
How far from its usual level
+27.0
Same report last year
23K
History used
1,567 days
2024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M
the 15 Dec 2025 report24 earlier reportsnormal: 90K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Jan 2026

Avalo Therapeutics had 2.6M shares sold short in the 31 Dec 2025 report, 128× the same report last year.

This period
2.6M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
93K
Typical spread (median absolute deviation)
47K
How far from its usual level
+35.4
Same report last year
20K
History used
1,583 days
2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M
the 31 Dec 2025 report24 earlier reportsnormal: 93K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Jan 2026

Avalo Therapeutics had 3.0M shares sold short in the 15 Jan 2026 report, 53× the same report last year.

This period
3.0M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
98K
Typical spread (median absolute deviation)
52K
How far from its usual level
+37.3
Same report last year
56K
History used
1,598 days
2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M
the 15 Jan 2026 report24 earlier reportsnormal: 98K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

Avalo Therapeutics saw 30 13F filers open a new position in the quarter ended 31 Dec 2025, 4.3× the same quarter last year.

This period
30 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
6.5
Typical spread (median absolute deviation)
2
How far from its usual level
+7.8
Same quarter last year
7
History used
1,553 days
2023-12-31: 32024-03-31: 82024-06-30: 62024-09-30: 112024-12-31: 72025-03-31: 52025-06-30: 42025-09-30: 312025-12-31: 30
the quarter ended 31 Dec 20258 earlier quartersnormal: 6.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 11 Feb 2026

Avalo Therapeutics had 3.2M shares sold short in the 30 Jan 2026 report, 74× the same report last year.

This period
3.2M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
108K
Typical spread (median absolute deviation)
62K
How far from its usual level
+33.5
Same report last year
43K
History used
1,613 days
2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M
the 30 Jan 2026 report24 earlier reportsnormal: 108K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Feb 2026

Avalo Therapeutics had 3.6M shares sold short in the 13 Feb 2026 report, 47× the same report last year.

This period
3.6M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
117K
Typical spread (median absolute deviation)
71K
How far from its usual level
+33.0
Same report last year
76K
History used
1,627 days
2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M
the 13 Feb 2026 report24 earlier reportsnormal: 117K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Mar 2026

Avalo Therapeutics had 3.7M shares sold short in the 27 Feb 2026 report, 41× the same report last year.

This period
3.7M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
141K
Typical spread (median absolute deviation)
95K
How far from its usual level
+25.1
Same report last year
91K
History used
1,641 days
2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M2026-02-27: 3.7M
the 27 Feb 2026 report24 earlier reportsnormal: 141K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Mar 2026

Avalo Therapeutics had 4.1M shares sold short in the 13 Mar 2026 report, 43× the same report last year.

This period
4.1M (the 13 Mar 2026 report)
Normal report (median of 24 earlier)
183K
Typical spread (median absolute deviation)
140K
How far from its usual level
+18.8
Same report last year
96K
History used
1,655 days
2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M2026-02-27: 3.7M2026-03-13: 4.1M
the 13 Mar 2026 report24 earlier reportsnormal: 183K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Apr 2026

Avalo Therapeutics had 5.5M shares sold short in the 31 Mar 2026 report, 48× the same report last year.

This period
5.5M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
723K
Typical spread (median absolute deviation)
671K
How far from its usual level
+4.8
Same report last year
116K
History used
1,673 days
2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M2026-02-27: 3.7M2026-03-13: 4.1M2026-03-31: 5.5M
the 31 Mar 2026 report24 earlier reportsnormal: 723K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 5 Nov 2026Filings record

    A major agreement ended

  2. 23 Jun 2026Filings record

    Director or officer change

  3. 12 Jun 2026Filings record

    Director or officer change

  4. 8 Jun 2026Filings record

    Director or officer change

  5. 15 May 2026Institutional holdings change

    saw 30 13F filers open a new position in the quarter ended 31 Mar 2026, 6.0× the same quarter last year.

    Same quarter last year: 5; its normal quarter is 7.5.

    See the evidence
    This period
    30 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    7.5
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +5.1
    Same quarter last year
    5
    History used
    1,643 days
    2024-03-31: 82024-06-30: 62024-09-30: 112024-12-31: 72025-03-31: 52025-06-30: 42025-09-30: 312025-12-31: 302026-03-31: 30
    the quarter ended 31 Mar 20268 earlier quartersnormal: 7.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  6. 11 Apr 2026Short interest and volume change

    had 5.5M shares sold short in the 31 Mar 2026 report, 48× the same report last year.

    Same report last year: 116K; its normal report is 723K.

    See the evidence
    This period
    5.5M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    723K
    Typical spread (median absolute deviation)
    671K
    How far from its usual level
    +4.8
    Same report last year
    116K
    History used
    1,673 days
    2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M2026-02-27: 3.7M2026-03-13: 4.1M2026-03-31: 5.5M
    the 31 Mar 2026 report24 earlier reportsnormal: 723K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 27 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 27 Mar 2026Filings record

    Director or officer change

  9. 25 Mar 2026Short interest and volume change

    had 4.1M shares sold short in the 13 Mar 2026 report, 43× the same report last year.

    Same report last year: 96K; its normal report is 183K.

    See the evidence
    This period
    4.1M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    183K
    Typical spread (median absolute deviation)
    140K
    How far from its usual level
    +18.8
    Same report last year
    96K
    History used
    1,655 days
    2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M2026-02-27: 3.7M2026-03-13: 4.1M
    the 13 Mar 2026 report24 earlier reportsnormal: 183K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 11 Mar 2026Short interest and volume change

    had 3.7M shares sold short in the 27 Feb 2026 report, 41× the same report last year.

    Same report last year: 91K; its normal report is 141K.

    See the evidence
    This period
    3.7M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    141K
    Typical spread (median absolute deviation)
    95K
    How far from its usual level
    +25.1
    Same report last year
    91K
    History used
    1,641 days
    2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M2026-02-27: 3.7M
    the 27 Feb 2026 report24 earlier reportsnormal: 141K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 26 Feb 2026Short interest and volume change

    had 3.6M shares sold short in the 13 Feb 2026 report, 47× the same report last year.

    Same report last year: 76K; its normal report is 117K.

    See the evidence
    This period
    3.6M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    117K
    Typical spread (median absolute deviation)
    71K
    How far from its usual level
    +33.0
    Same report last year
    76K
    History used
    1,627 days
    2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M
    the 13 Feb 2026 report24 earlier reportsnormal: 117K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 17 Feb 2026Institutional holdings change

    saw 30 13F filers open a new position in the quarter ended 31 Dec 2025, 4.3× the same quarter last year.

    Same quarter last year: 7; its normal quarter is 6.5.

    See the evidence
    This period
    30 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    6.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +7.8
    Same quarter last year
    7
    History used
    1,553 days
    2023-12-31: 32024-03-31: 82024-06-30: 62024-09-30: 112024-12-31: 72025-03-31: 52025-06-30: 42025-09-30: 312025-12-31: 30
    the quarter ended 31 Dec 20258 earlier quartersnormal: 6.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  13. 11 Feb 2026Short interest and volume change

    had 3.2M shares sold short in the 30 Jan 2026 report, 74× the same report last year.

    Same report last year: 43K; its normal report is 108K.

    See the evidence
    This period
    3.2M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    108K
    Typical spread (median absolute deviation)
    62K
    How far from its usual level
    +33.5
    Same report last year
    43K
    History used
    1,613 days
    2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M
    the 30 Jan 2026 report24 earlier reportsnormal: 108K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 28 Jan 2026Short interest and volume change

    had 3.0M shares sold short in the 15 Jan 2026 report, 53× the same report last year.

    Same report last year: 56K; its normal report is 98K.

    See the evidence
    This period
    3.0M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    98K
    Typical spread (median absolute deviation)
    52K
    How far from its usual level
    +37.3
    Same report last year
    56K
    History used
    1,598 days
    2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M
    the 15 Jan 2026 report24 earlier reportsnormal: 98K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 13 Jan 2026Short interest and volume change

    had 2.6M shares sold short in the 31 Dec 2025 report, 128× the same report last year.

    Same report last year: 20K; its normal report is 93K.

    See the evidence
    This period
    2.6M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    93K
    Typical spread (median absolute deviation)
    47K
    How far from its usual level
    +35.4
    Same report last year
    20K
    History used
    1,583 days
    2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M
    the 31 Dec 2025 report24 earlier reportsnormal: 93K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 25 Dec 2025Short interest and volume change

    had 1.9M shares sold short in the 15 Dec 2025 report, 81× the same report last year.

    Same report last year: 23K; its normal report is 90K.

    See the evidence
    This period
    1.9M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    90K
    Typical spread (median absolute deviation)
    44K
    How far from its usual level
    +27.0
    Same report last year
    23K
    History used
    1,567 days
    2024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M
    the 15 Dec 2025 report24 earlier reportsnormal: 90K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 10 Dec 2025Short interest and volume change

    had 1.8M shares sold short in the 28 Nov 2025 report, 354× the same report last year.

    Same report last year: 5,218; its normal report is 88K.

    See the evidence
    This period
    1.8M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    88K
    Typical spread (median absolute deviation)
    42K
    How far from its usual level
    +28.2
    Same report last year
    5,218
    History used
    1,550 days
    2024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M
    the 28 Nov 2025 report24 earlier reportsnormal: 88K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 26 Nov 2025Short interest and volume change

    had 1.8M shares sold short in the 14 Nov 2025 report, 188× the same report last year.

    Same report last year: 9,775; its normal report is 85K.

    See the evidence
    This period
    1.8M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    85K
    Typical spread (median absolute deviation)
    39K
    How far from its usual level
    +30.4
    Same report last year
    9,775
    History used
    1,536 days
    2024-11-15: 9,7752024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M
    the 14 Nov 2025 report24 earlier reportsnormal: 85K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 18 Nov 2025several at once

    saw 31 13F filers open a new position in the quarter ended 30 Sep 2025, 2.8× the same quarter last year, while it had 4.1M shares sold short in the 13 Mar 2026 report, 43× the same report last year. Two unrelated kinds of activity within 168 days.

    See the evidence (14 changes)

    Short interest and volume: Short interest spike became public on 25 Oct 2025

    Avalo Therapeutics had 1.3M shares sold short in the 15 Oct 2025 report, 26× the same report last year.

    This period
    1.3M (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    66K
    Typical spread (median absolute deviation)
    27K
    How far from its usual level
    +24.7
    Same report last year
    49K
    History used
    1,506 days
    2024-10-15: 49K2024-10-31: 10K2024-11-15: 9,7752024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M
    the 15 Oct 2025 report24 earlier reportsnormal: 66K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2025

    Avalo Therapeutics saw 31 13F filers open a new position in the quarter ended 30 Sep 2025, 2.8× the same quarter last year.

    This period
    31 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    6.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +8.2
    Same quarter last year
    11
    History used
    1,461 days
    2023-09-30: 92023-12-31: 32024-03-31: 82024-06-30: 62024-09-30: 112024-12-31: 72025-03-31: 52025-06-30: 42025-09-30: 31
    the quarter ended 30 Sep 20258 earlier quartersnormal: 6.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 13 Nov 2025

    Avalo Therapeutics had 1.3M shares sold short in the 31 Oct 2025 report, 134× the same report last year.

    This period
    1.3M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    80K
    Typical spread (median absolute deviation)
    36K
    How far from its usual level
    +23.6
    Same report last year
    10K
    History used
    1,522 days
    2024-10-31: 10K2024-11-15: 9,7752024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M
    the 31 Oct 2025 report24 earlier reportsnormal: 80K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Nov 2025

    Avalo Therapeutics had 1.8M shares sold short in the 14 Nov 2025 report, 188× the same report last year.

    This period
    1.8M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    85K
    Typical spread (median absolute deviation)
    39K
    How far from its usual level
    +30.4
    Same report last year
    9,775
    History used
    1,536 days
    2024-11-15: 9,7752024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M
    the 14 Nov 2025 report24 earlier reportsnormal: 85K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Dec 2025

    Avalo Therapeutics had 1.8M shares sold short in the 28 Nov 2025 report, 354× the same report last year.

    This period
    1.8M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    88K
    Typical spread (median absolute deviation)
    42K
    How far from its usual level
    +28.2
    Same report last year
    5,218
    History used
    1,550 days
    2024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M
    the 28 Nov 2025 report24 earlier reportsnormal: 88K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Dec 2025

    Avalo Therapeutics had 1.9M shares sold short in the 15 Dec 2025 report, 81× the same report last year.

    This period
    1.9M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    90K
    Typical spread (median absolute deviation)
    44K
    How far from its usual level
    +27.0
    Same report last year
    23K
    History used
    1,567 days
    2024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M
    the 15 Dec 2025 report24 earlier reportsnormal: 90K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Jan 2026

    Avalo Therapeutics had 2.6M shares sold short in the 31 Dec 2025 report, 128× the same report last year.

    This period
    2.6M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    93K
    Typical spread (median absolute deviation)
    47K
    How far from its usual level
    +35.4
    Same report last year
    20K
    History used
    1,583 days
    2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M
    the 31 Dec 2025 report24 earlier reportsnormal: 93K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 28 Jan 2026

    Avalo Therapeutics had 3.0M shares sold short in the 15 Jan 2026 report, 53× the same report last year.

    This period
    3.0M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    98K
    Typical spread (median absolute deviation)
    52K
    How far from its usual level
    +37.3
    Same report last year
    56K
    History used
    1,598 days
    2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M
    the 15 Jan 2026 report24 earlier reportsnormal: 98K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

    Avalo Therapeutics saw 30 13F filers open a new position in the quarter ended 31 Dec 2025, 4.3× the same quarter last year.

    This period
    30 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    6.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +7.8
    Same quarter last year
    7
    History used
    1,553 days
    2023-12-31: 32024-03-31: 82024-06-30: 62024-09-30: 112024-12-31: 72025-03-31: 52025-06-30: 42025-09-30: 312025-12-31: 30
    the quarter ended 31 Dec 20258 earlier quartersnormal: 6.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 11 Feb 2026

    Avalo Therapeutics had 3.2M shares sold short in the 30 Jan 2026 report, 74× the same report last year.

    This period
    3.2M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    108K
    Typical spread (median absolute deviation)
    62K
    How far from its usual level
    +33.5
    Same report last year
    43K
    History used
    1,613 days
    2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M
    the 30 Jan 2026 report24 earlier reportsnormal: 108K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Feb 2026

    Avalo Therapeutics had 3.6M shares sold short in the 13 Feb 2026 report, 47× the same report last year.

    This period
    3.6M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    117K
    Typical spread (median absolute deviation)
    71K
    How far from its usual level
    +33.0
    Same report last year
    76K
    History used
    1,627 days
    2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M
    the 13 Feb 2026 report24 earlier reportsnormal: 117K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Mar 2026

    Avalo Therapeutics had 3.7M shares sold short in the 27 Feb 2026 report, 41× the same report last year.

    This period
    3.7M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    141K
    Typical spread (median absolute deviation)
    95K
    How far from its usual level
    +25.1
    Same report last year
    91K
    History used
    1,641 days
    2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M2026-02-27: 3.7M
    the 27 Feb 2026 report24 earlier reportsnormal: 141K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Mar 2026

    Avalo Therapeutics had 4.1M shares sold short in the 13 Mar 2026 report, 43× the same report last year.

    This period
    4.1M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    183K
    Typical spread (median absolute deviation)
    140K
    How far from its usual level
    +18.8
    Same report last year
    96K
    History used
    1,655 days
    2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M2026-02-27: 3.7M2026-03-13: 4.1M
    the 13 Mar 2026 report24 earlier reportsnormal: 183K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Apr 2026

    Avalo Therapeutics had 5.5M shares sold short in the 31 Mar 2026 report, 48× the same report last year.

    This period
    5.5M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    723K
    Typical spread (median absolute deviation)
    671K
    How far from its usual level
    +4.8
    Same report last year
    116K
    History used
    1,673 days
    2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M2025-11-14: 1.8M2025-11-28: 1.8M2025-12-15: 1.9M2025-12-31: 2.6M2026-01-15: 3.0M2026-01-30: 3.2M2026-02-13: 3.6M2026-02-27: 3.7M2026-03-13: 4.1M2026-03-31: 5.5M
    the 31 Mar 2026 report24 earlier reportsnormal: 723K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  20. 14 Nov 2025Institutional holdings change

    saw 31 13F filers open a new position in the quarter ended 30 Sep 2025, 2.8× the same quarter last year.

    Same quarter last year: 11; its normal quarter is 6.5.

    See the evidence
    This period
    31 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    6.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +8.2
    Same quarter last year
    11
    History used
    1,461 days
    2023-09-30: 92023-12-31: 32024-03-31: 82024-06-30: 62024-09-30: 112024-12-31: 72025-03-31: 52025-06-30: 42025-09-30: 31
    the quarter ended 30 Sep 20258 earlier quartersnormal: 6.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  21. 13 Nov 2025Short interest and volume change

    had 1.3M shares sold short in the 31 Oct 2025 report, 134× the same report last year.

    Same report last year: 10K; its normal report is 80K.

    See the evidence
    This period
    1.3M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    80K
    Typical spread (median absolute deviation)
    36K
    How far from its usual level
    +23.6
    Same report last year
    10K
    History used
    1,522 days
    2024-10-31: 10K2024-11-15: 9,7752024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M2025-10-31: 1.3M
    the 31 Oct 2025 report24 earlier reportsnormal: 80K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 25 Oct 2025Short interest and volume change

    had 1.3M shares sold short in the 15 Oct 2025 report, 26× the same report last year.

    Same report last year: 49K; its normal report is 66K.

    See the evidence
    This period
    1.3M (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    66K
    Typical spread (median absolute deviation)
    27K
    How far from its usual level
    +24.7
    Same report last year
    49K
    History used
    1,506 days
    2024-10-15: 49K2024-10-31: 10K2024-11-15: 9,7752024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M2025-10-15: 1.3M
    the 15 Oct 2025 report24 earlier reportsnormal: 66K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 10 Oct 2025Short interest and volume change

    had 1.2M shares sold short in the 30 Sep 2025 report, 23× the same report last year.

    Same report last year: 54K; its normal report is 56K.

    See the evidence
    This period
    1.2M (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    56K
    Typical spread (median absolute deviation)
    34K
    How far from its usual level
    +23.7
    Same report last year
    54K
    History used
    1,491 days
    2024-09-30: 54K2024-10-15: 49K2024-10-31: 10K2024-11-15: 9,7752024-11-29: 5,2182024-12-13: 23K2024-12-31: 20K2025-01-15: 56K2025-01-31: 43K2025-02-14: 76K2025-02-28: 91K2025-03-14: 96K2025-03-31: 116K2025-04-15: 100K2025-04-30: 45K2025-05-15: 86K2025-05-30: 47K2025-06-13: 84K2025-06-30: 119K2025-07-15: 164K2025-07-31: 41K2025-08-15: 90K2025-08-29: 56K2025-09-15: 202K2025-09-30: 1.2M
    the 30 Sep 2025 report24 earlier reportsnormal: 56K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 1 Oct 2025Filings record

    Director or officer change

  25. 22 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 22 Sep 2025Filings record

    Director or officer change

  27. 18 Jun 2025Filings record

    Director or officer change

  28. 5 Jun 2025Filings record

    A major agreement ended

  29. 26 Mar 2025Filings record

    Director or officer change

  30. 2 Jan 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 2 Jan 2025Filings record

    Director or officer change

  32. 15 Nov 2024Insiders record

    Almenoff June Sherie (director) bought 1,000 shares of AVTX ($12,750) (dated 14 Nov 2024)

  33. 14 Aug 2024Filings record

    Director or officer change

  34. 16 Jul 2024Filings record

    Director or officer change

  35. 24 Jun 2024Filings record

    Director or officer change

  36. 23 May 2024Filings record

    Delisting notice or listing transfer

  37. 9 Apr 2024Filings record

    Private placement of securities (Form D)

  38. 28 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 28 Mar 2024Filings record

    Director or officer change

  40. 28 Mar 2024Filings record

    Delisting notice or listing transfer

Showing the newest 40 of 168 entries; narrow the window or the kind of data to see older ones.

Not listed: 236 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001534120
Ticker
AVTX
Domain
avalotx.com
Hq location
PA|WAYNE|19087 (1 unverified)
Lobbying client
avalo therapeutics
Name
Avalo Therapeutics, Inc., Cerecor Inc.
Uei
J7WVEQTH1ML6
  • Federal lobbying disclosures (LDA)2 records, 33 data points26 Mar 2021 to 31 Dec 2023
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)281 records12 Jan 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)735 data points31 Dec 2012 to 2 Nov 2026
  • SEC Form 4 insider transactions146 records, 476 data points9 May 2017 to 18 Sep 2026
  • FINRA short interest (twice monthly)372 data points31 Aug 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2632 data points26 Aug 2021 to 20 Nov 2026
  • USASpending.gov federal awards2 records, 21 data points8 Aug 2011 to 1 Oct 2021